L
LequteMan
Guest
A vaccine developed by the U.S. National Institute for Allergy and Infectious Diseases (NIAID) in collaboration with GlaxoSmithKline and the United States Army Medical Research Institute for infectious diseases will be subject to first human trials starting next week, #PNCVoice says.
Excerpt:
The trial will be sponsored by the National Institutes of Health (NIH), after the vaccine was fast-tracked for testing to tackle the Ebola outbreak which has killed more than 1,500 people out of more than 3,000 infected in Liberia, West Africa and Guinea.
To conduct the trial, 20 healthy adults aged 18-50 will be enrolled to test the vaccine’s safety and see whether it prompts the body to generate an immune response. The study will be conducted at NIH headquarters in Bethesda, Md.
NIH and British medical foundations will separately test the vaccine in #Britain, #Gambia and #Mali. The Centers for Disease Control and Prevention is discussing a trial in #Nigeria.
click here to read more
#Ebola #Vaccine
Excerpt:
The trial will be sponsored by the National Institutes of Health (NIH), after the vaccine was fast-tracked for testing to tackle the Ebola outbreak which has killed more than 1,500 people out of more than 3,000 infected in Liberia, West Africa and Guinea.
To conduct the trial, 20 healthy adults aged 18-50 will be enrolled to test the vaccine’s safety and see whether it prompts the body to generate an immune response. The study will be conducted at NIH headquarters in Bethesda, Md.
NIH and British medical foundations will separately test the vaccine in #Britain, #Gambia and #Mali. The Centers for Disease Control and Prevention is discussing a trial in #Nigeria.
click here to read more
#Ebola #Vaccine
